{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-12T16:28:13.715176+00:00","company":{"ticker":"VRDN","cik":1590750,"company_name":"Viridian Therapeutics, Inc.\\DE"},"pagination":{"limit":100,"returned":41,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Hercules Capital, Inc.","detail":"credit_facility","count":1,"first_seen":"2026-05-28T20:05:08+00:00","last_seen":"2026-05-28T20:05:08+00:00","evidence_fact_ids":[84880]},{"display_name":"Jefferies LLC and Leerink Partners LLC","detail":"underwriting","count":1,"first_seen":"2024-01-19T23:59:59+00:00","last_seen":"2024-01-19T23:59:59+00:00","evidence_fact_ids":[80640]},{"display_name":"U.S. Bank Trust Company, National Association","detail":"notes_offering","count":1,"first_seen":"2026-05-11T20:02:12+00:00","last_seen":"2026-05-11T20:02:12+00:00","evidence_fact_ids":[108375]},{"display_name":"Watch City Ventures MT, LLC","detail":"lease","count":1,"first_seen":"2024-04-16T23:59:59+00:00","last_seen":"2024-04-16T23:59:59+00:00","evidence_fact_ids":[61609]},{"display_name":"WuXi Biologics Limited","detail":"supply","count":1,"first_seen":"2026-05-26T20:05:16+00:00","last_seen":"2026-05-26T20:05:16+00:00","evidence_fact_ids":[87064]}],"lender":[{"display_name":"U.S. Bank Trust Company, National Association","detail":"convertible_notes","count":1,"first_seen":"2026-05-11T20:02:12+00:00","last_seen":"2026-05-11T20:02:12+00:00","evidence_fact_ids":[55313]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"f97863185cbbb236c20f29419834dbc81c80e263","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-06-03T11:00:22+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"207,355","votes_against":null,"votes_for":"86,084,347","votes_withheld":null}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"4. Approval, on an advisory basis, of the frequency of holding an advisory vote on the compensation of the Company’s named executive officers: 1 Year 2 Years 3 Years Abstain 86,084,347 29,762 517,682 207,355","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254560","anchor_url":"https://secwatch.observer/filing/0001193125-26-254560#claim-f97863185cbbb236c20f29419834dbc81c80e263","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm"},{"fact_type":"shareholder_vote","fact_key":"fdfd1c2d63caf56741e9bd2499507cc51c16cd0d","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-06-03T11:00:22+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Approval, on an advisory basis, of the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"6,733,104","subject":null,"votes_abstain":"213,336","votes_against":"3,113,724","votes_for":"83,512,086","votes_withheld":null}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-02 meeting.","evidence_excerpt":"3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 83,512,086 3,113,724 213,336 6,733,104","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254560","anchor_url":"https://secwatch.observer/filing/0001193125-26-254560#claim-fdfd1c2d63caf56741e9bd2499507cc51c16cd0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e46bdd0a155975d789eb4278ebe12ed59cbcf2fd","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-06-03T11:00:22+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"193,660","votes_against":"512,582","votes_for":"92,866,008","votes_withheld":null}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-02 meeting.","evidence_excerpt":"2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions Broker Non-Votes 92,866,008 512,582 193,660 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254560","anchor_url":"https://secwatch.observer/filing/0001193125-26-254560#claim-e46bdd0a155975d789eb4278ebe12ed59cbcf2fd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f12202a7b55b8b6fc70ae635e023089dbece1759","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-06-03T11:00:22+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-02","outcome":"passed","proposal_text":"Election of two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"6,733,104","subject":"Tomas Kiselak","votes_abstain":null,"votes_against":null,"votes_for":"72,363,500","votes_withheld":"14,475,646"},{"broker_non_votes":"6,733,104","subject":"Jennifer K. Moses","votes_abstain":null,"votes_against":null,"votes_for":"86,378,842","votes_withheld":"460,304"}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Election of two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders at the 2026-06-02 meeting.","evidence_excerpt":"1. Election of the two Class II director nominees to serve until the 2029 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 72,363,500 14,475,646 6,733,104 Jennifer K. Moses 86,378,842 460,304 6,733,104","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-254560","anchor_url":"https://secwatch.observer/filing/0001193125-26-254560#claim-f12202a7b55b8b6fc70ae635e023089dbece1759","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526254560/0001193125-26-254560-index.htm"},{"fact_type":"material_agreement","fact_key":"9b98d32785943d55df2bd1107bb3b5f269fcfcaf","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-28T20:05:08+00:00","payload":{"action":"termination","agreement_name":"Loan Agreement","agreement_type":"credit_facility","counterparty":"Hercules Capital, Inc.","effective_date":"2026-05-27","item_codes_triggered":["1.02"],"value_text":"approximately $55.1 million"},"claim":"Viridian Therapeutics, Inc.\\DE terminated Loan Agreement with Hercules Capital, Inc. valued at approximately $55.1 million (effective 2026-05-27).","evidence_excerpt":"On May 27, 2026, Viridian Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $55.1 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement, entered into and effective as of April 1, 2022, by and among the Company, certain of its subsidiaries from time to time party thereto, Hercules Capital, Inc. (“Hercules”) and certain other lenders named therein, which was subsequently amended on August 7, 2023 and October 17, 2025 (as amended, the “Loan Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-245186","anchor_url":"https://secwatch.observer/filing/0001193125-26-245186#claim-9b98d32785943d55df2bd1107bb3b5f269fcfcaf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526245186/0001193125-26-245186-index.htm"},{"fact_type":"material_agreement","fact_key":"e5e744a37b80fc6d213207066b8932e9177d6b0a","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-26T20:05:16+00:00","payload":{"action":"entry","agreement_name":"Commercial Manufacturing Services Agreement","agreement_type":"supply","counterparty":"WuXi Biologics (Hong Kong) Limited","effective_date":"2026-05-24","item_codes_triggered":["1.01"],"value_text":null},"claim":"Viridian Therapeutics, Inc.\\DE entered into Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited (effective 2026-05-24).","evidence_excerpt":"On May 24, 2026, Viridian Therapeutics, Inc. (the “Company”) entered into a Commercial Manufacturing Services Agreement (the “Agreement”) with WuXi Biologics (Hong Kong) Limited (“WuXi Biologics”) pursuant to which WuXi Biologics will manufacture and supply the Company’s anticipated long-term supply requirements of veligrotug drug substance and drug product for commercial use (the “Product”), if approved.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-239246","anchor_url":"https://secwatch.observer/filing/0001193125-26-239246#claim-e5e744a37b80fc6d213207066b8932e9177d6b0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/0001193125-26-239246-index.htm"},{"fact_type":"material_agreement","fact_key":"ff1c44a925adb1ea4966674f5de54828910a7d8d","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-11T20:02:12+00:00","payload":{"action":"entry","agreement_name":"Indenture","agreement_type":"notes_offering","counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-11","item_codes_triggered":["1.01"],"value_text":"$250,000,000 aggregate principal amount"},"claim":"Viridian Therapeutics, Inc.\\DE entered into Indenture with U.S. Bank Trust Company, National Association valued at $250,000,000 aggregate principal amount (effective 2026-05-11).","evidence_excerpt":"On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-216709","anchor_url":"https://secwatch.observer/filing/0001193125-26-216709#claim-ff1c44a925adb1ea4966674f5de54828910a7d8d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/0001193125-26-216709-index.htm"},{"fact_type":"debt_financing","fact_key":"f2d57660c72b9bbf356339332936273be65e7c6e","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-11T20:02:12+00:00","payload":{"counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-05-11","event":"incurrence","instrument_type":"convertible_notes","interest_rate_text":"1.75%","item_codes_triggered":["2.03"],"maturity_text":"May 15, 2032","principal_text":"250,000,000"},"claim":"Viridian Therapeutics, Inc.\\DE incurred convertible notes of 250,000,000 with U.S. Bank Trust Company, National Association at 1.75% maturing May 15, 2032.","evidence_excerpt":"On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments.","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001193125-26-216709","anchor_url":"https://secwatch.observer/filing/0001193125-26-216709#claim-f2d57660c72b9bbf356339332936273be65e7c6e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/0001193125-26-216709-index.htm"},{"fact_type":"earnings_release","fact_key":"8e8280d0456dc22bfadcb411621e1cd853146d04","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"Viridian Therapeutics, Inc.\\DE reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Viridian Therapeutics, Inc. issued a press release reporting financial results for the quarter ended March 31, 2026.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-205010","anchor_url":"https://secwatch.observer/filing/0001193125-26-205010#claim-8e8280d0456dc22bfadcb411621e1cd853146d04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526205010/0001193125-26-205010-index.htm"},{"fact_type":"executive_change","fact_key":"a702b4dfaa","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-04-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jeff Ajer was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On April 2, 2025, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”), appointed Jeff Ajer to serve as a Class I director of the Company, effective as of April 7, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-073937","anchor_url":"https://secwatch.observer/filing/0001193125-25-073937#claim-a702b4dfaa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525073937/0001193125-25-073937-index.htm"},{"fact_type":"executive_change","fact_key":"43bfdcfdd9","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-03-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Peter Harwin resigned as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On March 5, 2025, Peter Harwin, a member of the Board, notified the Company of his decision to resign as a member of the Board effective as of March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-050880","anchor_url":"https://secwatch.observer/filing/0001193125-25-050880#claim-43bfdcfdd9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm"},{"fact_type":"executive_change","fact_key":"4ea31f13d5","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-03-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christopher Cain was appointed as Class I Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"appointed Christopher Cain, Ph.D., the Director of Research at Fairmount Funds Management LLC, to serve as a Class I director of the Company, chairperson of the Nominating and Corporate Governance Committee, and member of the Audit Committee and Science & Technology Committee, effective as of March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-050880","anchor_url":"https://secwatch.observer/filing/0001193125-25-050880#claim-4ea31f13d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525050880/0001193125-25-050880-index.htm"},{"fact_type":"executive_change","fact_key":"a2aaec8152","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-01-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Seth Harmon was appointed as Chief Financial Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On January 7, 2025, the Board of Directors of Viridian Therapeutics, Inc. (the “Company”) appointed Seth Harmon to serve as the Chief Financial Officer of the Company effective as of January 1, 2025.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-25-004435","anchor_url":"https://secwatch.observer/filing/0001193125-25-004435#claim-a2aaec8152","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525004435/0001193125-25-004435-index.htm"},{"fact_type":"earnings_release","fact_key":"0d0a0b3a292669c72d1d713741baa27e7388fa42","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$48.5 million","period_text":"first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":null},"claim":"Viridian Therapeutics, Inc.\\DE reported first quarter ended March 31, 2024 results: net income $48.5 million.","evidence_excerpt":"The company’s net loss was $48.5 million for the first quarter ended March 31, 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-133770","anchor_url":"https://secwatch.observer/filing/0001193125-24-133770#claim-0d0a0b3a292669c72d1d713741baa27e7388fa42","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524133770/0001193125-24-133770-index.htm"},{"fact_type":"material_agreement","fact_key":"9b7b433e2fa0e866ded6d214b9a5e345b748720a","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Fourth Amendment to Lease Agreement","agreement_type":"lease","counterparty":"Watch City Ventures MT, LLC","effective_date":"2024-04-08","item_codes_triggered":["1.01"],"value_text":"base rent $38,232.33 per month for first year, increasing 2% annually; tenant improvement allowance"},"claim":"Viridian Therapeutics, Inc.\\DE amended Fourth Amendment to Lease Agreement with Watch City Ventures MT, LLC valued at base rent $38,232.33 per month for first year, increasing 2% annually; tenant improvement allowance (effective 2024-04-08).","evidence_excerpt":"On April 10, 2024, Viridian Therapeutics, Inc. (the “Company”) entered into a Fourth Amendment to Lease Agreement (the “Amendment”), effective April 8, 2024, with Watch City Ventures MT, LLC (“Landlord\"), to amend that certain Lease, dated January 13, 2020, by and between the Company and Landlord (the “Lease\"), as amended on July 6, 2021, April 13, 2022 and July 29, 2022, for the lease of an aggregate of 10,956 square feet of rentable area of the building located at 221 Crescent Street, Waltham, Massachusetts (the “Original Premises\"), which serves as the Company’s headquarters.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-097728","anchor_url":"https://secwatch.observer/filing/0001193125-24-097728#claim-9b7b433e2fa0e866ded6d214b9a5e345b748720a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524097728/0001193125-24-097728-index.htm"},{"fact_type":"earnings_release","fact_key":"d3907d59f1f3647c8b5f38e50f0c51457ccf18d6","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-02-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2023","report_date":"2024-02-27","result_type":"preliminary_results","revenue_text":null},"claim":"Viridian Therapeutics, Inc.\\DE reported preliminary financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"Viridian Therapeutics, Inc. (the “Company”) issued a press release reporting financial results for the fourth quarter and year ended December 31, 2023.","confidence":0.8,"filing_url":"https://secwatch.observer/filing/0001193125-24-047916","anchor_url":"https://secwatch.observer/filing/0001193125-24-047916#claim-d3907d59f1f3647c8b5f38e50f0c51457ccf18d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/0001193125-24-047916-index.htm"},{"fact_type":"material_agreement","fact_key":"6cad146668e38c44d6865090914c22a9e1c225c5","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Jefferies LLC and Leerink Partners LLC","effective_date":"2024-01-17","item_codes_triggered":["1.01"],"value_text":"approximately $150.0 million"},"claim":"Viridian Therapeutics, Inc.\\DE entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC valued at approximately $150.0 million (effective 2024-01-17).","evidence_excerpt":"On January 17, 2024, Viridian Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC (collectively, the “Representatives”) relating to the offer and sale (the “Offering”) of 7,142,858 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a public offering price of $21.00 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-011355","anchor_url":"https://secwatch.observer/filing/0001193125-24-011355#claim-6cad146668e38c44d6865090914c22a9e1c225c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524011355/0001193125-24-011355-index.htm"},{"fact_type":"executive_change","fact_key":"0806d2a319","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-01-03","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Dr. Thomas Ciulla was appointed as Chief Medical Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"The Board of Directors of the Company appointed Dr. Thomas Ciulla, formerly the Company’s Chief Development Officer since February 2023, as Chief Medical Officer of the Company effective January 3, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-003936","anchor_url":"https://secwatch.observer/filing/0001193125-24-003936#claim-0806d2a319","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/0001193125-24-003936-index.htm"},{"fact_type":"executive_change","fact_key":"b92583a558","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"ceased to serve","action_category":"departure","departure_tone":"routine","effective_date":"2024-01-03","interim":false,"role":"Chief Medical Officer","role_category":"other_named_officer","successor_name":"Dr. Thomas Ciulla","successor_named":true},"claim":"Dr. Barrett Katz departed as Chief Medical Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On January 3, 2024, after discussions with Viridian Therapeutics, Inc. (the “Company”) regarding his future plans, Dr. Barrett Katz, age 74, transitioned to a consulting role and ceased to serve as Chief Medical Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-003936","anchor_url":"https://secwatch.observer/filing/0001193125-24-003936#claim-b92583a558","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312524003936/0001193125-24-003936-index.htm"},{"fact_type":"governance_change","fact_key":"761c0c07d10a2cf085c87df6a907d3b1b52ae4ee","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-12-18T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-12-15","item_codes_triggered":["5.03"],"summary_text":"Amended bylaws to designate federal district courts as sole and exclusive forum for Securities Act claims."},"claim":"Viridian Therapeutics, Inc.\\DE: Amended bylaws to designate federal district courts as sole and exclusive forum for Securities Act claims (effective 2023-12-15).","evidence_excerpt":"Effective December 15, 2023, the board of directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) adopted the Fourth Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws have been amended to designate the federal district courts of the United States as the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the “Securities Act”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-297131","anchor_url":"https://secwatch.observer/filing/0001193125-23-297131#claim-761c0c07d10a2cf085c87df6a907d3b1b52ae4ee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523297131/0001193125-23-297131-index.htm"},{"fact_type":"earnings_release","fact_key":"a0955cd4c243798ea658bdb0eff433736ed6061c","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"Viridian Therapeutics, Inc.\\DE reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the quarter ended September 30, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-276007","anchor_url":"https://secwatch.observer/filing/0001193125-23-276007#claim-a0955cd4c243798ea658bdb0eff433736ed6061c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523276007/0001193125-23-276007-index.htm"},{"fact_type":"governance_change","fact_key":"c50e7e8f7eb1a1abef44b919e81660ac74afd69b","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-11-02T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2023-11-01","item_codes_triggered":["5.03"],"summary_text":"The Board adopted the Third Amended and Restated Bylaws, modifying the notice period required to call a special meeting of the Board."},"claim":"Viridian Therapeutics, Inc.\\DE: The Board adopted the Third Amended and Restated Bylaws, modifying the notice period required to call a special meeting of the Board (effective 2023-11-01).","evidence_excerpt":"Effective November 1, 2023, the Board adopted the Third Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws, among other things, modify the notice period required to call a special meeting of the Board.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-269415","anchor_url":"https://secwatch.observer/filing/0001193125-23-269415#claim-c50e7e8f7eb1a1abef44b919e81660ac74afd69b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm"},{"fact_type":"executive_change","fact_key":"61728244ea","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-11-02T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-10-29","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Scott Myers resigned as director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On October 29, 2023, Scott Myers resigned as a member of the board of directors (the \"Board\") of Viridian Therapeutics, Inc. (the \"Company\"), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-269415","anchor_url":"https://secwatch.observer/filing/0001193125-23-269415#claim-61728244ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523269415/0001193125-23-269415-index.htm"},{"fact_type":"material_agreement","fact_key":"42ded7cf9012418fcd7128efc44e2a28bcf105e6","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional and accredited investors","effective_date":"2023-10-30","item_codes_triggered":["1.01"],"value_text":"approximately $185 million"},"claim":"Viridian Therapeutics, Inc.\\DE entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $185 million (effective 2023-10-30).","evidence_excerpt":"On October 30, 2023, Viridian Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-265717","anchor_url":"https://secwatch.observer/filing/0001193125-23-265717#claim-42ded7cf9012418fcd7128efc44e2a28bcf105e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm"},{"fact_type":"executive_change","fact_key":"8711e2dc07","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stephen Mahoney was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"Mr. Mahoney was also appointed to the Company’s Board of Directors (the “Board”) as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-265717","anchor_url":"https://secwatch.observer/filing/0001193125-23-265717#claim-8711e2dc07","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm"},{"fact_type":"executive_change","fact_key":"f062df71c6","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-10-30T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-10-30","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Stephen Mahoney was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On October 30, 2023, the Company announced the appointment of Stephen Mahoney as the Company’s President and Chief Executive Officer, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-265717","anchor_url":"https://secwatch.observer/filing/0001193125-23-265717#claim-f062df71c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523265717/0001193125-23-265717-index.htm"},{"fact_type":"executive_change","fact_key":"732842b345","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-09-25T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-09-21","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Sarah Gheuens was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"Effective September 21, 2023, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed a new director, Dr. Sarah Gheuens, to serve as a Class I director to hold office until the 2025 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-240931","anchor_url":"https://secwatch.observer/filing/0001193125-23-240931#claim-732842b345","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523240931/0001193125-23-240931-index.htm"},{"fact_type":"executive_change","fact_key":"f9df007dc6","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-09-12T23:59:59+00:00","payload":{"action":"assumed the role","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-09-12","interim":false,"role":"principal financial and accounting officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Seth Harmon changed role as principal financial and accounting officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"on September 12, 2023, Seth Harmon, the Company’s Senior Vice President of Finance, assumed the role of the Company’s principal financial and accounting officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-233500","anchor_url":"https://secwatch.observer/filing/0001193125-23-233500#claim-f9df007dc6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm"},{"fact_type":"executive_change","fact_key":"e4440805f7","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-09-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-09-12","interim":false,"role":"Chief Financial Officer and Chief Business Officer","role_category":"cfo","successor_name":"Seth Harmon","successor_named":true},"claim":"Kristian Humer resigned as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On September 8, 2023, Kristian Humer, the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics, Inc. (the “Company”), resigned, effective September 12, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-233500","anchor_url":"https://secwatch.observer/filing/0001193125-23-233500#claim-e4440805f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523233500/0001193125-23-233500-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4e6c6ada4e2057e2abf82dd03d5cabc1f0271cf4","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder","proposal_type":"equity_plan","results":[{"broker_non_votes":"4,287,967","subject":null,"votes_abstain":"19,666","votes_against":"12,404,022","votes_for":"22,896,437","votes_withheld":null}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder.","evidence_excerpt":"4. Approval of a further amendment and restatement of the Company’s Amended and Restated 2016 Equity Incentive Plan, including an increase by 2,000,000 of the shares reserved for issuance thereunder: For Against Abstentions Broker Non-Votes 22,896,437 12,404,022 19,666 4,287,967","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-169038","anchor_url":"https://secwatch.observer/filing/0001193125-23-169038#claim-4e6c6ada4e2057e2abf82dd03d5cabc1f0271cf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f634b7cd5acdd2ffeaad628909b2c818d2ce12d6","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval, on an advisory basis, of the compensation of the Company’s named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"4,287,967","subject":null,"votes_abstain":"21,844","votes_against":"12,351,317","votes_for":"22,946,964","votes_withheld":null}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers.","evidence_excerpt":"3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers: For Against Abstentions Broker Non-Votes 22,946,964 12,351,317 21,844 4,287,967","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-169038","anchor_url":"https://secwatch.observer/filing/0001193125-23-169038#claim-f634b7cd5acdd2ffeaad628909b2c818d2ce12d6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cd2c280fd8c3bd3a315a428e9fb061aade898b58","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"10,580","votes_against":"9,049","votes_for":"39,588,463","votes_withheld":null}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023.","evidence_excerpt":"2. Ratification of the selection of KPMG LLP as the Company’s independent auditor for 2023: For Against Abstentions Broker Non-Votes 39,588,463 9,049 10,580 0","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-169038","anchor_url":"https://secwatch.observer/filing/0001193125-23-169038#claim-cd2c280fd8c3bd3a315a428e9fb061aade898b58","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm"},{"fact_type":"shareholder_vote","fact_key":"30567c4f8e204f1b4681e5ea7390a9611e2edc1d","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-06-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders","proposal_type":"director_election","results":[{"broker_non_votes":"4,287,967","subject":"Tomas Kiselak","votes_abstain":null,"votes_against":null,"votes_for":"26,435,249","votes_withheld":"8,884,876"},{"broker_non_votes":"4,287,967","subject":"Jennifer K. Moses","votes_abstain":null,"votes_against":null,"votes_for":"34,979,960","votes_withheld":"340,165"}]},"claim":"Viridian Therapeutics, Inc.\\DE shareholders approved Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders.","evidence_excerpt":"1. Election of the two Class II director nominees to serve until the 2026 Annual Meeting of Stockholders: For Withheld Broker Non-Votes Tomas Kiselak 26,435,249 8,884,876 4,287,967 Jennifer K. Moses 34,979,960 340,165 4,287,967","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-169038","anchor_url":"https://secwatch.observer/filing/0001193125-23-169038#claim-30567c4f8e204f1b4681e5ea7390a9611e2edc1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523169038/0001193125-23-169038-index.htm"},{"fact_type":"earnings_release","fact_key":"6dbcdc48b3bd17dd0179c6e14a56e25bf084cddf","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-05-09T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2023","report_date":"2023-05-09","result_type":"reported_results","revenue_text":null},"claim":"Viridian Therapeutics, Inc.\\DE reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced financial results and provided a corporate update for the first quarter ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-23-139409","anchor_url":"https://secwatch.observer/filing/0001193125-23-139409#claim-6dbcdc48b3bd17dd0179c6e14a56e25bf084cddf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523139409/0001193125-23-139409-index.htm"},{"fact_type":"executive_change","fact_key":"82e56f8461","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-04-12T23:59:59+00:00","payload":{"action":"ceased to serve","action_category":"departure","departure_tone":"routine","effective_date":"2023-04-11","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Carrie Melvin departed as Chief Operating Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On April 12, 2023, Viridian Therapeutics, Inc. (the “Company”) announced that Carrie Melvin has ceased to serve as the Company’s Chief Operating Officer, effective April 11, 2023.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-23-098482","anchor_url":"https://secwatch.observer/filing/0001193125-23-098482#claim-82e56f8461","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523098482/0001193125-23-098482-index.htm"},{"fact_type":"earnings_release","fact_key":"ac44d44cf8432809e0b92b56fc5105c710b93a9a","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-03-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and full year ended December 31, 2022","report_date":"2023-03-08","result_type":"reported_results","revenue_text":null},"claim":"Viridian Therapeutics, Inc.\\DE reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On March 8, 2023, Viridian Therapeutics, Inc. (the “Company”), issued a press release reporting financial results for the fourth quarter and year ended December 31, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-063737","anchor_url":"https://secwatch.observer/filing/0001193125-23-063737#claim-ac44d44cf8432809e0b92b56fc5105c710b93a9a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523063737/0001193125-23-063737-index.htm"},{"fact_type":"executive_change","fact_key":"9b1629ad65","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-02-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-02-06","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Scott Myers was appointed as Class III Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"Mr. Myers was also appointed as a Class III Director","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-024877","anchor_url":"https://secwatch.observer/filing/0001193125-23-024877#claim-9b1629ad65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm"},{"fact_type":"executive_change","fact_key":"6c22349114","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-02-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-02-06","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Scott Myers was appointed as President and Chief Executive Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"appointment of Scott Myers as the Company’s President and Chief Executive Officer, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-23-024877","anchor_url":"https://secwatch.observer/filing/0001193125-23-024877#claim-6c22349114","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523024877/0001193125-23-024877-index.htm"},{"fact_type":"executive_change","fact_key":"addde376db","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2022-06-23T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-21","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Carrie Melvin was appointed as Chief Operating Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On June 21, 2022, the board of directors of Viridian Therapeutics, Inc. (the “Company”) appointed Carrie Melvin as Chief Operating Officer of the Company, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-179235","anchor_url":"https://secwatch.observer/filing/0001193125-22-179235#claim-addde376db","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/0001193125-22-179235-index.htm"},{"fact_type":"executive_change","fact_key":"7d323b3773","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2021-07-26T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-07-26","interim":false,"role":"Chief Financial Officer and Chief Business Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Kristian Humer was appointed as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On July 26, 2021, Viridian Therapeutics, Inc. (the “Company”) announced the appointment of Kristian Humer as the Company’s Chief Financial Officer and Chief Business Officer, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-223656","anchor_url":"https://secwatch.observer/filing/0001193125-21-223656#claim-7d323b3773","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312521223656/0001193125-21-223656-index.htm"},{"fact_type":"executive_change","fact_key":"9e82f61947","cik":1590750,"ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2021-07-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-07-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Jennifer K. Moses was appointed as Director at Viridian Therapeutics, Inc.\\DE.","evidence_excerpt":"On July 14, 2021, the board of directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) appointed Jennifer K. Moses as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-216388","anchor_url":"https://secwatch.observer/filing/0001193125-21-216388#claim-9e82f61947","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312521216388/0001193125-21-216388-index.htm"}]}